Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGVN | PRESS-RELEASE | mixed | 6/10 | Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million upfront through a mix | Mar 11, 2026 |
| TNYA | PRESS-RELEASE | mixed | 6/10 | Tenaya Therapeutics reported financial results for Q4 and full year 2025, highlighted by reduced net loss and a strength | Mar 11, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral therapy for LGMD2I/R9, sh | Mar 11, 2026 |
| SLDB | PRESS-RELEASE | bullish | 8/10 | Solid Biosciences reported updated positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing | Mar 11, 2026 |
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine announced the continuation of participant enrollment in the third cohort of its FDA-approved Phase I/ | Mar 11, 2026 |
| QNRX | PRESS-RELEASE | bullish | 7/10 | Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation for QRX003 lotion (4%) for the treatment | Mar 11, 2026 |
| OGEN | PRESS-RELEASE | neutral | 4/10 | Oragenics, Inc. announced it is exploring potential acquisitions of CNS-focused assets that align with its proprietary i | Mar 11, 2026 |
| VRCA | PRESS-RELEASE | bullish | 8/10 | Verrica Pharmaceuticals reported strong 2025 financial results with total revenue surging 370% year-over-year to $35.6 m | Mar 11, 2026 |
| TPST | PRESS-RELEASE | bullish | 7/10 | Tempest Therapeutics selected Cincinnati Children’s AGCTC as its contract development and manufacturing partner to advan | Mar 11, 2026 |
| AAPG | PRESS-RELEASE | neutral | 3/10 | Ascentage Pharma announced it will release its full year 2025 unaudited financial results on March 25–26, 2026, with inv | Mar 11, 2026 |
| SGMT | PRESS-RELEASE | mixed | 6/10 | Sagimet Biosciences reported financial results for Q4 and full year 2025, highlighting a reduced net loss despite flat R | Mar 11, 2026 |
| KMDA | PRESS-RELEASE | bullish | 8/10 | Kamada Ltd. reported strong 2025 full-year results with revenue of $180.5 million (up 12% YoY), adjusted EBITDA of $42.0 | Mar 11, 2026 |
| KMDA | PRESS-RELEASE | neutral | 4/10 | Kamada Ltd. declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, payable on April 6, 2026, | Mar 11, 2026 |
| NERV | PRESS-RELEASE | mixed | 6/10 | Minerva Neurosciences reported Q4 and full-year 2025 financial results, highlighted by a $80.0 million upfront private p | Mar 11, 2026 |
| ARVN | PRESS-RELEASE | neutral | 5/10 | Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be pres | Mar 11, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) us | Mar 11, 2026 |
| VACH | PRESS-RELEASE | bearish | 8/10 | Voyager Acquisition Corp. completed its business combination with VERAXA Biotech AG, but approximately 99.67% of public | Mar 11, 2026 |
| DNTH | PRESS-RELEASE | neutral | 6/10 | Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants | Mar 10, 2026 |
| QNTM | PRESS-RELEASE | neutral | 4/10 | Quantum BioPharma (QNTM) announced it will release its Q4 and full-year 2025 financial results on March 24, 2026. Concur | Mar 10, 2026 |
| ARTV | PRESS-RELEASE | neutral | 4/10 | Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83.9 million, increase | Mar 10, 2026 |
| TRVI | PRESS-RELEASE | neutral | 3/10 | Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial resu | Mar 10, 2026 |
| NATR | PRESS-RELEASE | bullish | 7/10 | Nature's Sunshine Products (NATR) reported strong Q4 and full-year 2025 results, with revenue up 4.7% and 5.7% respectiv | Mar 10, 2026 |
| SKYE | PRESS-RELEASE | mixed | 6/10 | Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesit | Mar 10, 2026 |
| VTVT | PRESS-RELEASE | mixed | 6/10 | vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 m | Mar 10, 2026 |
| BTAI | PRESS-RELEASE | bearish | 7/10 | BioXcel Therapeutics is raising approximately $8.0 million through a registered direct offering of 4.5 million shares an | Mar 10, 2026 |
| SPRC | PRESS-RELEASE | mixed | 6/10 | SciSparc Ltd. (SPRC) announced that its majority-owned subsidiary, NeuroThera Labs, is acquiring 54.01% of quantum techn | Mar 10, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a service agreement with FyoniBio GmbH to develop and validate a pharmacokinetics (PK) assay | Mar 10, 2026 |
| IMA | PRESS-RELEASE | neutral | 4/10 | ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million p | Mar 10, 2026 |
| TARA | PRESS-RELEASE | bullish | 8/10 | Protara Therapeutics reported strong interim clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC), s | Mar 10, 2026 |
| PVLA | PRESS-RELEASE | neutral | 3/10 | Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patien | Mar 10, 2026 |